(2)
LOS ANGELES, CA / ACCESSWIRE / January 7, 2021 / Cannabis Global, Inc. (OTC PINK:CBGL), an innovation-oriented company investing in disruptive cannabis and hemp-related technologies and Marijuana Company of America (OTC PINK:MCOA), each of which is the largest shareholder of the other, today discuss planned strategies to target the coming national market for cannabis, as the Democratic Party is set to take control of the U.S. Senate, thus controlling the legislative agenda for the foreseeable future. Both Companies believe there will be congressional action to lift prohibitions on cannabis, creating a new national market for cannabis and cannabis products.
Arman Tabatabaei and Jesus Quintero, CEOs of CBGL and MCOA, respectively, jointly commented, With the Democratic Party controlling the executive and legislative branches, the prospects for ultimate passage of the MORE Act, which will remove cannabis from the list of federally controlled substances, are excellent and we predi
Marijuana Company of America and Cannabis Global Prepare for Robust Cannabis Market as Democrats Poised to Drive Legislative Agenda
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Cannabis Global and Marijuana Company of America Position for National Cannabis Markets as Democrats Set to Drive the Legislative Agenda
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021
American BriVision Holding CorporationJanuary 6, 2021 GMT
Fremont, CA - ( NewMediaWire ) - January 06, 2021 - American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, yesterday issued a letter to its more than 700 shareholders describing the company’s achievements in 2020 and goals for 2021. The letter from Dr. Howard Doong, CEO of ABVC, is reprinted below in its entirety.
Dear Shareholder:
Now that 2020 has ended, we believe it will be informative to you, our shareholders, to hear about our goals for 2021. But first, we note that 2020 was an exceptional year for the company, particularly with respect to our medical device, Vitargus(R), and our